Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022

<br /> Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022<br />

PR Newswire

HOLON,

Israel

,

Oct. 31, 2022

/PRNewswire/ —

Compugen Ltd.

(Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its third quarter 2022 financial results on

Monday, November 14, 2022

, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at

8:30 AM ET

.

As part of the update, management will discuss Compugen’s data to be presented at the Annual Meeting of the Society for Immunotherapy of Cancer, being held on

November 8-12, 2022

.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S.,

or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen’s website, located at the following

link

Following the live webcast, a replay will be available on the Company’s website.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Partnered programs include bapotulimab, an antibody targeting ILDR2, in Phase 1 development, licensed to Bayer under a research and discovery collaboration and license agreement, and a TIGIT/PD-1 bispecific derived from COM902 (AZD2936) in Phase 1/2 development by AstraZeneca through a license agreement for the development of bispecific and multi-specific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The most advanced program, COM503 is about to enter pre-IND enabling studies. COM503 is a potential first-in-class, high affinity antibody targeting cytokine biology to enhance anti-tumor immunity in a differentiated manner. Compugen is headquartered in

Israel

, with offices in South San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:

Yvonne Naughton

, Ph.D.

Head of Investor Relations and Corporate Communications

Email:

[email protected]

Tel: +1 (628) 241-0071